Bibliography
- Iverson SD, Iversen LL. Dopamine: 50 years in perspective. Trends Neurosci 2007;30:188-93
- Lavreysen H, Dautzenberg FM. Therapeutic potential of group III metabotropic glutamate receptors. Curr Med Chem 2008;15:671-84
- Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005;6:787-98
- Beurrier C, Lopez S, Re´vy D, Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB 2009;23:3619-28
- Marino MJ, Williams DL, Jr, O'Brien JA, Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci USA 2003;100:13668-73
- Battaglia G, Busceti CL, Molinaro G, Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine. J Neurosci 2006;26:7222-9
- Hopkins CR, Lindsley CW, Niswender CM. mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease. Future Med Chem 2009;1:501-13
- Conn PJ, Christopoulos A, Lindsley, CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Disc 2009;8:41-54
- Addex Partner Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator. Available from: http://www.addexpharma.com/press-releases/press-release-details/article/addex-partner-starts-first-ever- clinical-trial-of-an-mglur-positive- allosteric-modulator/
- Niswender CM, Johnson KA, Weaver CD, Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol 2008;74:1345–58
- Williams RW, Johnson KA, Gentry PR, Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4). Bioorg Med Chem Lett 2009;19:4967-70
- Niswender CM, Lebois EP, Luo Q, Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): part I. discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Bioorg Med Chem Lett 2008;18:5626-30
- Williams R, Niswender CM, Luo Q, Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: challenges in hit-to-lead. Bioorg Med Chem Lett 2009;19:962-6
- Addex Pharma S.A. Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO2009010454; 2009
- Engers DW, Niswender CM, Weaver CD, Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J Med Chem 2009;52:4115-18
- Lindsley CW, Niswender CM, Engers DW, Hopkins CR. Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease. Curr Top Med Chem 2009;9:949-63
- Addex Pharma S.A. Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO2009010455; 2009
- Sharma S, Kedrowski J, Rook JM, Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl) pyrimidines. J Med Chem 2009;52:4103-6
- Addex Achieves Second Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc. Available from: http://www.addexpharma.com/press-releases/press-release-details/article/ addex-achieves-second-milestone- in-parkinsons-disease-collaboration- with-merck-co-inc/
- Addex Extends Parkinson's Disease Collaboration with Merck & Co., Inc. Available from: http://www.addexpharma.com/press-releases/press-release-details/article/addex-extends-parkinsons-disease- collaboration-with-merck-co-inc/